Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$69.73 - $142.9 $71,752 - $147,044
-1,029 Closed
0 $0
Q4 2021

Feb 01, 2022

BUY
$134.56 - $217.97 $62,570 - $101,356
465 Added 82.45%
1,029 $147,000
Q3 2021

Nov 12, 2021

BUY
$177.8 - $270.58 $8,890 - $13,529
50 Added 9.73%
564 $117,000
Q2 2021

Aug 10, 2021

SELL
$121.0 - $257.67 $31,581 - $67,251
-261 Reduced 33.68%
514 $109,000
Q1 2021

Apr 30, 2021

SELL
$112.98 - $319.93 $52,309 - $148,127
-463 Reduced 37.4%
775 $141,000
Q4 2020

Jan 25, 2021

SELL
$78.74 - $139.5 $76,299 - $135,175
-969 Reduced 43.91%
1,238 $138,000
Q3 2020

Nov 12, 2020

BUY
$79.44 - $178.51 $33,523 - $75,331
422 Added 23.64%
2,207 $239,000
Q2 2020

Aug 13, 2020

BUY
$13.86 - $83.61 $24,740 - $149,243
1,785 New
1,785 $149,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $704M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Centaurus Financial, Inc. Portfolio

Follow Centaurus Financial, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Centaurus Financial, Inc. with notifications on news.